fda warning letters glp-1 compounders october 2025 Guest Letter: Concerns About Compounded GLP-1 Medications | STOP Obesity Alliance | Milken Institute School of Public Health

FDA Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling

29.10

★★★★☆4.8 (126)

The FDA has sent 30 warning letters to telehealth companies for falsely marketing compounded GLP-1s, which are not FDA-approved and can pose risks to patients. FULL STORY:🔗https://tinyurl.com/3ztf9uj2

27.70

★★★★★4.9 (98)

Trends In FDA FY 2025 Warning Letters

26.70

★★★★★5.0 (157)

The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide

28.65

★★★★★4.7 (84)

Congress Introduces SAFE Drugs Act of 2025, Expanding FDA Oversight of Compounded GLP-1 Drugs and Telehealth Providers

26.04

★★★★★4.9 (203)

FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products

26.22

★★★★★5.0 (176)

The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide

24.45

★★★★★4.8 (132)